Literature DB >> 28495931

Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition.

Elmar Pieterse1, Nils Rother1, Marjolein Garsen1, Julia M Hofstra1, Simon C Satchell1, Markus Hoffmann1, Markus A Loeven1, Hanneke K Knaapen1, Olivier W H van der Heijden1, Jo H M Berden1, Luuk B Hilbrands1, Johan van der Vlag2.   

Abstract

OBJECTIVE: An excessive release and impaired degradation of neutrophil extracellular traps (NETs) leads to the continuous exposure of NETs to the endothelium in a variety of hematologic and autoimmune disorders, including lupus nephritis. This study aims to unravel the mechanisms through which NETs jeopardize vascular integrity. APPROACH AND
RESULTS: Microvascular and macrovascular endothelial cells were exposed to NETs, and subsequent effects on endothelial integrity and function were determined in vitro and in vivo. We found that endothelial cells have a limited capacity to internalize NETs via the receptor for advanced glycation endproducts. An overflow of the phagocytic capacity of endothelial cells for NETs resulted in the persistent extracellular presence of NETs, which rapidly altered endothelial cell-cell contacts and induced vascular leakage and transendothelial albumin passage through elastase-mediated proteolysis of the intercellular junction protein VE-cadherin. Furthermore, NET-associated elastase promoted the nuclear translocation of junctional β-catenin and induced endothelial-to-mesenchymal transition in cultured endothelial cells. In vivo, NETs could be identified in kidney samples of diseased MRL/lpr mice and patients with lupus nephritis, in whom the glomerular presence of NETs correlated with the severity of proteinuria and with glomerular endothelial-to-mesenchymal transition.
CONCLUSIONS: These results indicate that an excess of NETs exceeds the phagocytic capacity of endothelial cells for NETs and promotes vascular leakage and endothelial-to-mesenchymal transition through the degradation of VE-cadherin and the subsequent activation of β-catenin signaling. Our data designate NET-associated elastase as a potential therapeutic target in the prevention of endothelial alterations in diseases characterized by aberrant NET release.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  endothelial cells; extracellular traps; leukocyte elastase; lupus erythematosus, systemic; lupus nephritis

Mesh:

Substances:

Year:  2017        PMID: 28495931     DOI: 10.1161/ATVBAHA.117.309002

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  66 in total

1.  Protease Activity in Vascular Disease.

Authors:  Megan A Slack; Scott M Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-25       Impact factor: 8.311

Review 2.  To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps.

Authors:  Sebastian Boeltz; Poorya Amini; Hans-Joachim Anders; Felipe Andrade; Rostyslav Bilyy; Simon Chatfield; Iwona Cichon; Danielle M Clancy; Jyaysi Desai; Tetiana Dumych; Nishant Dwivedi; Rachael Ann Gordon; Jonas Hahn; Andrés Hidalgo; Markus H Hoffmann; Mariana J Kaplan; Jason S Knight; Elzbieta Kolaczkowska; Paul Kubes; Moritz Leppkes; Angelo A Manfredi; Seamus J Martin; Christian Maueröder; Norma Maugeri; Ioannis Mitroulis; Luis E Munoz; Daigo Nakazawa; Indira Neeli; Victor Nizet; Elmar Pieterse; Marko Z Radic; Christiane Reinwald; Konstantinos Ritis; Patrizia Rovere-Querini; Michal Santocki; Christine Schauer; Georg Schett; Mark Jay Shlomchik; Hans-Uwe Simon; Panagiotis Skendros; Darko Stojkov; Peter Vandenabeele; Tom Vanden Berghe; Johan van der Vlag; Ljubomir Vitkov; Maren von Köckritz-Blickwede; Shida Yousefi; Alexander Zarbock; Martin Herrmann
Journal:  Cell Death Differ       Date:  2019-01-08       Impact factor: 15.828

3.  Aggregated neutrophil extracellular traps resolve inflammation by proteolysis of cytokines and chemokines and protection from antiproteases.

Authors:  Jonas Hahn; Christine Schauer; Christine Czegley; Lasse Kling; Lenka Petru; Benjamin Schmid; Daniela Weidner; Christiane Reinwald; Mona H C Biermann; Stefan Blunder; Jürgen Ernst; Adam Lesner; Tobias Bäuerle; Ralf Palmisano; Silke Christiansen; Martin Herrmann; Aline Bozec; Robert Gruber; Georg Schett; Markus H Hoffmann
Journal:  FASEB J       Date:  2018-08-21       Impact factor: 5.191

4.  Citrullinated histone 3 causes endothelial barrier dysfunction.

Authors:  Jamie E Meegan; Xiaoyuan Yang; Richard S Beard; Melanie Jannaway; Victor Chatterjee; Thomas E Taylor-Clark; Sarah Y Yuan
Journal:  Biochem Biophys Res Commun       Date:  2018-07-17       Impact factor: 3.575

Review 5.  Neutrophil Extracellular Traps and Liver Disease.

Authors:  Moira B Hilscher; Vijay H Shah
Journal:  Semin Liver Dis       Date:  2019-11-14       Impact factor: 6.115

Review 6.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

7.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 8.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

Review 9.  Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system.

Authors:  Masaki Honda; Paul Kubes
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 46.802

10.  Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus.

Authors:  Stanley Moore; Hsin-Hsuan Juo; Christoffer T Nielsen; Helena Tyden; Anders A Bengtsson; Christian Lood
Journal:  J Rheumatol       Date:  2019-12-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.